<DOC>
	<DOCNO>NCT00611559</DOCNO>
	<brief_summary>The new formulation administer 4th consecutive dose compare current formulation vaccine partially double blind study . The study double-blind respect two DTPa-HBV-IPV/Hib group . The study open respect DTPa-HBV-IPV group .</brief_summary>
	<brief_title>Study New Formulation DTPa-HBV-IPV/Hib Vaccine Administered Booster Dose 18-23 Months Old Children</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . Subjects must complete full threedose primary vaccination course DTPaHBVIPV/Hib DTPaHBVIPV primary study DTPaHBVIPV109 ( study NCT00320463 ) . A male female , include 18 23 month age time booster vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Planned administration/ administration vaccine foreseen study protocol within 30 day booster dose . Participation another clinical study , primary study NCT00320463 present booster study , time study , subject expose investigational noninvestigational product . Previous booster vaccination diphtheria , tetanus , pertussis , poliomyelitis hepatitis B since conclusion visit study NCT00320463 . Previous booster vaccination Haemophilus influenzae disease DTPaHBVIPV/Hib group , since conclusion visit study NCT00320463 . History exposure diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B and/or Haemophilus influenzae disease since conclusion visit study NCT00320463 . Any confirm suspected immunosuppressive immunodeficient condition , base physical examination . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period . Any following adverse event occur previous administration DTP vaccine : Hypersensitivity reaction due vaccine . Encephalopathy define acute , severe central nervous system disorder unknown etiology occur within 7 day follow previous vaccination generally consist major alteration consciousness , unresponsiveness , generalized focal seizure persist hour , failure recover within 24 hour . Any following adverse event occur previous administration DTP vaccine : Temperature &gt; = 40.0 Â°C ( axillary temperature ) , within 48 hour vaccination . Collapse shocklike state within 48 hour vaccination . Persistent , inconsolable cry last &gt; = 3 hour , occur within 48 hour vaccination . Convulsions without fever , occur within 3 day vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Infanrix hexa</keyword>
	<keyword>combine vaccine</keyword>
</DOC>